- Molecular biological analyses
- Confocal Live Cell Imaging
- Characterization of T cell-, NK cell- and ILC-subpopulations
- Crosstalk of dendritic and natural killer cells
- Optimization of NK cell expansion and activation
- Viral and non-viral gene modification of immune cells
- Xenograft models for testing of new cell therapeutics
- Mouse models for tumors, leukemia, BMT, GVHD, GVL
- In vivo Imaging Facility
- Flow cytometry and cell sorting
- S1 / S2 areas for gene modification of immune and tumor cells
Prof. Dr. med. Evelyn Ullrich
Professorship for Cellular Immunology
Specialist for Internal Medicine
Building 32, Room E209
T +49 69 6301 - 83000
- Our scientific work focuses on immunological issues and research on complex immunological relationships in immunodeficiencies, haemato-oncological diseases and stem cell transplantation.
- Preclinical research projects and studies deal with molecular and functional characterization of cellular immune system components with a focus on the various subpopulations of T cells, Natural Killer (NK), Cytokine-Induced Killer (CIK) cells, and Innate Lymphoid Cells (ILCs ).
- In experimental models of stem cell transplantation, GVL and GVHD, complex molecular relationships in immunology are explored.
- In addition to molecular, cell biological and flow cytometric methods, modern in vitro and in vivo imaging techniques are used.
Using these techniques in a variety of preclinical models, innovative cell therapy protocols can be developed, including CAR immune cell therapies.
Range of Methods
- In the field of translational research, the Ullrich lab performs immunomonitoring studies of cancer patients undergoing specific treatments, autologous or allogeneic stem cell transplantation.
- Projects with focus on immunoregulation of graft-versus-leukemia (GVL) and graft-versus-host (GVH) effects in allogeneic stem cell transplantation have been supported by the German Cancer Aid as Max Eder Research Group and awarded with different international research prizes.
- The overall research aims are the optimization of personalized cellular therapy combined with immunomodulation in patients with advanced malignant diseases.
- Current projects focus on gene modification of immune cells and testing of CAR NK and CAR-T cell therapies.